https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50584 Wed 28 Feb 2024 15:06:35 AEDT ]]> Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28543 Wed 11 Apr 2018 15:37:28 AEST ]]> Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14865 Tue 13 Aug 2024 08:51:00 AEST ]]> Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20093 Sat 24 Mar 2018 08:00:06 AEDT ]]> Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29413 Sat 24 Mar 2018 07:36:21 AEDT ]]> Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29414 Sat 24 Mar 2018 07:36:12 AEDT ]]> Association of pembrolizumab with tumor response and survival among patients with advanced melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29369 Sat 24 Mar 2018 07:34:17 AEDT ]]>